Hikal Ltd vs Ipca Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Hikal Ltd is ₹ 189.85 as of 30 Apr 15:30 . The P/E Ratio of Hikal Ltd changed from 13.3 on March 2021 to 54.4 on March 2025 . This represents a CAGR of 32.54% over 5 yearsThe P/E Ratio of Ipca Laboratories Ltd changed from 21.2 on March 2021 to 51.6 on March 2025 . This represents a CAGR of 19.47% over 5 years The Market Cap of Hikal Ltd changed from ₹ 1769 crore on March 2021 to ₹ 4933 crore on March 2025 . This represents a CAGR of 22.76% over 5 yearsThe Market Cap of Ipca Laboratories Ltd changed from ₹ 24137 crore on March 2021 to ₹ 38088 crore on March 2025 . This represents a CAGR of 9.55% over 5 years The revenue of Hikal Ltd for the Dec '25 is ₹ 497.1 crore as compare to the Sep '25 revenue of ₹ 320.4 crore. This represent the growth of 55.15% The revenue of Ipca Laboratories Ltd for the Dec '25 is ₹ 2430 crore as compare to the Sep '25 revenue of ₹ 2584 crore. This represent the decline of -5.96% The ebitda of Hikal Ltd for the Dec '25 is ₹ 47.5 crore as compare to the Sep '25 ebitda of ₹ 9.1 crore. This represent the growth of 421.98% The ebitda of Ipca Laboratories Ltd for the Dec '25 is ₹ 571.19 crore as compare to the Sep '25 ebitda of ₹ 514.52 crore. This represent the growth of 11.01% The net profit of Hikal Ltd changed from ₹ 5.1 crore to ₹ -5.9 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Ipca Laboratories Ltd changed from ₹ 198.98 crore to ₹ 364.05 crore over 7 quarters. This represents a CAGR of 41.23% The Dividend Payout of Hikal Ltd changed from 18.52 % on March 2021 to 10.87 % on March 2025 . This represents a CAGR of -10.11% over 5 yearsThe Dividend Payout of Ipca Laboratories Ltd changed from 8.9 % on March 2021 to 15.59 % on March 2025 . This represents a CAGR of 11.86% over 5 years .

About Hikal Ltd

Hikal Limited, incorporated on July 8, 1988, has emerged as one of the preferred partners for global companies in segments such as pharmaceuticals, crop protection, animal health, biocides, and specialty chemicals.
The Company is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities. The Company has 5 manufacturing facilities across three states in India.
It supply products to customers across the globe in the US, Japan, Europe, Canada, South East Asia, LATAM, India and RoW. Apart from this, it specialize in manufacturing APIs and intermediates in pharmaceutical division.
Within pharmaceutical division, it offer human health and animal health products. Hikal commenced its first project in 1991 at its first greenfield site at M.

About Ipca Laboratories Ltd

Ipca Laboratories Limited (IPCA) was incorporated on 19 October, 1949 under the name of 'The Indian Pharmaceutical Combine Association Limited.' Ipca is a fully integrated, pharmaceutical company manufacturing and marketing over 350 formulations and 80 API's covering various therapeutic segments.
The products of the Company are now sold in over 100 countries across the globe.
The Company has 18 manufacturing units in India manufacturing API's and formulations for the world market. Ipca's APIs and Formulations produced at world class manufacturing facilities are approved by leading drug regulatory authorities including the US-Food and Drug Administration (FDA), UK-Medicines and Healthcare products Regulatory Agency (MHRA), South Africa-Medicines Control Council (MCC), Brazil-Brazilian National Health Vigilance Agency (ANVISA) and Australia-Therapeutic Goods Administration (TGA) with operations in over 100 countries.

FAQs for the comparison of Hikal Ltd and Ipca Laboratories Ltd

Which company has a larger market capitalization, Hikal Ltd or Ipca Laboratories Ltd?

Market cap of Hikal Ltd is 2,340 Cr while Market cap of Ipca Laboratories Ltd is 38,847 Cr

What are the key factors driving the stock performance of Hikal Ltd and Ipca Laboratories Ltd?

The stock performance of Hikal Ltd and Ipca Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Hikal Ltd and Ipca Laboratories Ltd?

As of May 3, 2026, the Hikal Ltd stock price is INR ₹189.85. On the other hand, Ipca Laboratories Ltd stock price is INR ₹1531.2.

How do dividend payouts of Hikal Ltd and Ipca Laboratories Ltd compare?

To compare the dividend payouts of Hikal Ltd and Ipca Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.